Akebia Therapeutics, Inc. (AKBA)
$
1.59
+0.02 (1.26%)
Key metrics
Financial statements
Free cash flow per share
0.1223
Market cap
421.9 Million
Price to sales ratio
1.8747
Debt to equity
5.1282
Current ratio
1.9369
Income quality
-2.0369
Average inventory
17.7 Million
ROE
-1.3767
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with kidney diseases. The company's lead investigational product candidate, vadadustat, is an oral therapy currently in Phase III trials aimed at treating anemia caused by chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis dependent adult patients. Additionally, Akebia provides Auryxia, a ferric citrate medication that helps control serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease (DD-CKD) and addresses iron deficiency anemia in those not on dialysis. The weighted average number of diluted shares outstanding is 210,946,658.00 reflecting potential dilution effects, while the company’s stock is identified with the symbol 'AKBA' in the market. Akebia has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat across a broad range of regions, including the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries. Furthermore, it has partnered with Mitsubishi Tanabe Pharma Corporation for similar efforts in Japan and other Asian markets. Akebia also maintains a research and license agreement with Janssen Pharmaceutica NV to advance hypoxia-inducible factor prolyl hydroxylase targeted compounds on a global scale. The company earned an interest income of $0.00 showcasing its financial investments, and incurred an income tax expense of $0.00 indicating its tax obligations. The net income ratio is -0.43 reflecting the company's profitability margin. The company's stock is affordable at $2.82 making it an appealing option for budget-conscious investors. Additionally, the stock has a high average trading volume of 4,248,914.00 indicating strong liquidity. With a market capitalization of $421,931,929.00 the company is classified as a small-cap player in the industry. Akebia Therapeutics is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth.
Is Akebia Therapeutics, Inc. (AKBA) a good investment?
Investing in Akebia Therapeutics, Inc. (AKBA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Akebia Therapeutics, Inc. (AKBA)'s stock forecast?
Analysts predict Akebia Therapeutics, Inc. stock to fluctuate between $1.45 (low) and $4.08 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Akebia Therapeutics, Inc.'s market capitalization?
As of 2025-12-04, Akebia Therapeutics, Inc.'s market cap is $421,931,929, based on 265,365,993 outstanding shares.
How does Akebia Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Akebia Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Akebia Therapeutics, Inc. (AKBA) stock?
To buy Akebia Therapeutics, Inc. (AKBA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AKBA. Place an order (Market, Limit, etc.).
What is the best time to invest in Akebia Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Akebia Therapeutics, Inc. perform in the last earnings report?
Revenue: $160,180,000 | EPS: -$0.33 | Growth: 17.86%.
Where can I find Akebia Therapeutics, Inc.'s investor relations reports?
Visit https://www.akebia.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Akebia Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Akebia Therapeutics, Inc. stock?
All-time high: $4.08 (2025-07-11) | All-time low: $0.24 (2022-10-24).
What are the key trends affecting Akebia Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
The heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
seekingalpha.com
Akebia Therapeutics, Inc. ( AKBA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO, President & Director Nicholas Grund - Senior VP & Chief Commercial Officer Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Andrew Kassin - BTIG, LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Jiale Song - Jefferies LLC, Research Division Presentation Operator Good day, and thank you for standing by.
globenewswire.com
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025
benzinga.com
Akebia Therapeutics Inc. (NASDAQ:AKBA) stock is trading lower on Wednesday.
globenewswire.com
Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA
seekingalpha.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Nicholas Grund - Senior VP & Chief Commercial Officer Presentation Unknown Analyst Good morning and thank you for joining us here today at the Wells Fargo Healthcare Conference. I'm joined with the team from Akebia today.
seekingalpha.com
I'm bullish on Akebia at $3.13, viewing the 21% post-earnings dip as a buying opportunity ahead of major revenue catalysts. Vafseo's rapid adoption and DaVita's pilot could double Akebia's addressable dialysis market, driving significant near-term revenue growth and profitability. Despite a mixed EPS, strong topline growth and stable Auryxia sales highlight Akebia's transition from speculative biotech to commercial-stage company.
seekingalpha.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P. Butler - CEO, President & Director Mercedes Carrasco - Senior Director of Investor & Corporate Communications Nicholas Grund - Senior VP & Chief Commercial Officer Conference Call Participants Julian Reed Harrison - BTIG, LLC, Research Division Mazahir Lukman Alimohamed - Leerink Partners LLC, Research Division Roger Song - Jefferies LLC, Research Division Operator Good day and thank you for standing by.
zacks.com
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
zacks.com
Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
See all news
